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Abstract
Background: Fluoro-L-thymidine (FLT) is a positron emission tomography/computed tomography (PET/CT) tracer
which reflects proliferative activity in a cancer lesion. The main objective of this prospective explorative study was
to evaluate whether FLT-PET can be used for the early evaluation of treatment response in colorectal cancer
patients (CRC) with liver metastases. Patients with metastatic CRC having at least one measurable (>1 cm) liver
metastasis receiving first-line chemotherapy were included. A FLT-PET/CT scan was performed at baseline and after the
first treatment. The maximum and mean standardised uptake values (SUVmax, SUVmean) were measured. After three
cycles of chemotherapy, treatment response was assessed by CT scan based on RECIST 1.1.
Results: Thirty-nine consecutive patients were included of which 27 were evaluable. Dropout was mainly due to disease
complications. Nineteen patients (70%) had a partial response, seven (26%) had stable disease and one (4%) had
progressive disease. A total of 23 patients (85%) had a decrease in FLT uptake following the first treatment. The patient
with progressive disease had the highest increase in FLT uptake in SUVmax. There was no correlation between the
response according to RECIST and the early changes in FLT uptake measured as SUVmax (p = 0.24).
Conclusions: No correlation was found between early changes in FLT uptake after the first cycle of treatment and the
response evaluated from subsequent CT scans. It seems unlikely that FLT-PET can be used on its own for the early
response evaluation of metastatic CRC.
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Background
Response evaluation during cancer treatment is normally
based on the response evaluation criteria in solid
tumours (RECIST) looking for tumour shrinkage [1].
However, molecular changes precede tumour shrinkage,
and therefore, there is an increased interest in functional
imaging in the search for early response evaluation
attributes [2, 3].
[18F]-3′-Deoxy-3′-fluorothymidine (FLT) is a modified
thymidine analogue developed as a positron emission
tomography (PET) tracer to reflect proliferation. FLT
crosses the cell membrane and becomes phosphorylated
by thymidine kinase 1 (TK-1), which is the first enzyme
in the salvage pathway of thymidine synthesis as part of
the DNA synthesis. FLT is not incorporated into the
DNA, but becomes dephosphorylated at a slow rate.
Phosphorylation causes FLT to be trapped inside the cell
for a relatively long period, making it suitable for tracer
imaging [4]. Several small studies have shown a correl-
ation between the uptake of FLT and the histopatho-
logical marker of proliferation Ki-67 [5]. It has also been
shown that FLT accumulates proportionally with TK-1
[6]. Furthermore, we have previously shown in pre-
clinical studies that FLT is a sensitive and early pre-
dictor of morphological therapy response in various
cancers [7–10].* Correspondence: marie.benzon.mogensen@regionh.dk;
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Colorectal cancer (CRC) is the third most common
type of cancer worldwide [11]. Approximately 20% of pa-
tients with newly diagnosed CRC have distant metasta-
ses at the time of diagnosis, the most common site being
the liver [11]. Moreover, another 50% of CRC patients
will develop liver metastases at some time during their
disease. The only definitive treatment for metastatic
CRC is surgical resection if possible [12]. A revolution in
the treatment of metastatic CRC has taken place in the
last decade—especially in the surgical field—resulting in
more patients being candidates for resection, which
has been followed by a significant improvement in
the 5-year survival rate of patients resected for liver me-
tastases [12]. It is therefore crucial to identify patients
who are not responding as early as possible as an ineffect-
ive treatment could jeopardise their chance of being can-
didates for resection. Furthermore, the benefit of saving
patients from unnecessary side effects of a treatment that
does not work is also worthwhile in a palliative setting.
Preclinical studies with cell lines and xenografts
[4, 13–16] as well as a few clinical studies [17, 18] have
suggested the possibility that FLT-PET could be used for
the early assessment of treatment response in CRC. To
the best of our knowledge, to date, the potential of FLT-
PET for the early response evaluation of CRC during
chemotherapy has been investigated in only three clinical
studies with 2, 12 and 18 patients, respectively [17–19].
Just one of these studies used liver metastases as measur-
able outcome lesions [17], while none of them used the
currently preferred treatment regimen, i.e. addition of a
targeting agent to the chemotherapy.
The present study therefore aimed to assess the poten-
tial of FLT-PET/computed tomography (CT) in the early
response evaluation of CRC based on measurable liver
metastases. The early changes in FLT uptake were
compared to RECIST after three cycles of treatment. It is
acknowledged that RECIST, especially after the introduc-
tion of bevacizumab, have limitations in response evalu-
ation in liver metastases since increasing necrosis does
not necessarily lead to tumour shrinkage [20, 21]. Hence,
it has been suggested that, in combination with volumet-
ric changes, the morphologic changes of liver metastases
such as, sharpness of the rim and the heterogeneity of
contrast enhancement seen on CT or magnetic reson-
ance (MR) may also be useful for evaluating response.
Although morphology is not included in the clinical
guidelines, a study by Chun and co-workers found that
morphological criteria based on attenuation changes on
CT correlated with the pathologic response and was as-
sociated to overall survival (OS) [20]. Therefore, in this
study, changes in FLT uptake shortly after the initiation
of treatment were compared not only to the outcome of
RECIST but also to the changes in attenuation of liver
lesions on CT after three treatment cycles.
Methods
Study design
The study was an explanatory prospective trial to assess
whether FLT-PET/CT can predict the response to first-
line chemotherapy in CRC with liver metastases early after
the initiation of chemotherapy. The primary outcome
measure was the standard anatomic response determined
using RECIST, version 1.1, applied on CT scans after three
treatment cycles. Tumour shrinkage is necessary for
resection to be possible in patients with only potentially
resectable disease. Therefore, an aggressive approach is
especially important in these cases. Tumour shrinkage
after three cycles was therefore chosen as the primary
endpoint. Furthermore, according to the criteria detailed
by Chun et al. [20], a morphologic response assessment
was performed based on the changes in attenuation seen
on CT after three cycles of treatment.
The study was conducted in accordance with the
Helsinki Declaration. All patients provided written con-
sent before participation. The study protocol was ap-
proved by the Regional Ethics Committee of The Capital
Region of Denmark (ref. no. H-3-2012-041).
Patient population
Patients referred to the Department of Oncology at
Rigshospitalet, Copenhagen University Hospital, for pallia-
tive or neoadjuvant treatment for CRC with liver metasta-
ses were considered for inclusion in the study. The
inclusion criteria were (i) at least one measurable liver me-
tastasis (>1 cm) on the diagnostic CT scan, (ii) histologically
confirmed adenocarcinoma in the primary tumour and (iii)
a ECOG performance status of 0–1 [22]. This meant that
patients with liver only as well as patients with more
advanced disease could be included. The patients were
required to be chemonaïve or to have completed adjuvant
chemotherapy at least 6 months prior to inclusion. Exclu-
sion criteria were (i) acute myocardial infarction within
6 months or unstable angina, (ii) previous allergic reaction
to a contrast agent, (iii) systolic blood pressure higher than
150 mmHg and (iv) patients not fit for two-drug cancer
treatment. Patients were treated with first-line chemother-
apy independently to this study according to local guide-
lines until disease progression, refusal of treatment, toxicity
criteria for discontinuation were met, possibility for surgical
resection or 9 months of treatment. The patients were
evaluated after every third treatment cycle or whenever
progression was suspected clinically.
RECIST evaluation
Changes seen on CT from baseline to evaluation after
three cycles of treatment were evaluated according to
RECIST 1.1. According to RECIST, a maximum of five le-
sions were included in the assessment, hereof maximum
two lesions per organ. All had at least one liver lesion
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included. The primary tumour was not included. Evalua-
tions were performed by a specialised radiologist. Accord-
ing to the guidelines, stable disease (SD) is defined as a
decrease in measurement of no more than 30% or an
increase less than 20% [1]. Patients having progressive
disease (PD) (i.e. increase of largest diameter of more than
20%) or SD were characterised as non-responders, while
responders were defined as patients experiencing partial
response (PR) or complete response (CR).
FLT-PET/CT imaging
FLT was routinely synthesised in-house according to
standard procedures [23]. Approximately 350 MBq was
injected intravenously approximately 60 min prior to
scanning in a Siemens Biograph 64 PET/CT scanner
(Siemens Health Care, Erlangen, Germany). The baseline
scan was performed with intravenous and oral contrast
media according to general clinical practice while the
follow-up scans were performed as PET/CT with low-
dose CT for attenuation correction purposes. The PET
acquisition time was 2–5 min per bed position depend-
ing on body mass index. The patients were scanned
from the skull base to proximal thighs. FLT-PET/CT
scans were obtained twice: before onset of the treatment
as baseline and after initiation of chemotherapy between
day 5 and 15 (mean; day 10).
Visually defined regions of interest were analysed
quantitatively on the FLT-PET scans by an experienced
nuclear medicine physician blinded to the RECIST out-
come on the evaluation scan after three cycles of treat-
ment. The same set of metastatic lesions depicted by the
radiologist as target lesions for RECIST was evaluated by
FLT-PET. FLT uptake was measured as maximum and
mean standardised uptake values (SUVmax, SUVmean).
The percentage changes of SUV between baseline and
evaluation scans were calculated for all target lesions.
Primary tumours were evaluated by both FLT/PET and
RECIST, but because of difficulties in performing accur-
ate repeated measures due to mobility of the primary
tumour, these measures were not included in the
RECIST and FLT/PET comparison.
Morphologic assessment
Using the criteria detailed by Chun et al. [20], an expert
liver radiologist assessed the morphologic changes ob-
served on CT. Each metastasis was assigned to one of
three morphology groups where group 1 was defined as
metastases with homogeneous low attenuation with a
thin, sharply defined tumour-liver interface, and group 3
was characterised by heterogeneous attenuation and a
thick, poorly defined tumour-liver interface. Metastases
that could not be allocated to these two groups were in-
cluded in group 2. The metastases were categorised on
the baseline CT as well as on the evaluation CT. An
optimal response was defined as reallocation of each
individual metastasis from group 3 or 2 to group 1. An
incomplete response was defined as reallocation from
group 3 to group 2. No response characterised metasta-
ses not changing groups.
Statistical analysis
The hypothesis of this study was that early changes in
FLT uptake might be predictive for response. The
Wilcoxon signed-rank test for paired data was used to
assess whether there were changes in FLT uptake mea-
sured as SUV from baseline to evaluation. To test for
differences in SUV measures between responders and
non-responders, the Mann-Whitney U test was used.
The primary endpoint was tumour shrinkage after three
cycles of treatment, and therefore, correlation between
early changes in SUV and the RECIST measurements
was tested by the Pearson correlation coefficient. A two-
sided p value less than 0.05 was considered statistically
significant. Cox regression analysis was performed to
test correlation between early FLT changes (percentage
change of FLT) and OS. The positive predictive value for
using early increase in FLT uptake as a predictor of pa-
tients with PD was calculated based on tumour growth
after three cycles of treatment. The statistical analyses
were performed with SPSS version 19 software (SPSS
Inc., IBM Company, NY, USA).
Results
Patient characteristics
Between June 2012 and November 2014, 39 chemonaïve
patients were recruited to the study (see the CONSORT
flow diagram in Fig. 1). Of these 39 patients, 12 were
excluded. Specifically, eight patients did not undergo
FLT-PET scanning primarily due to decreased perform-
ance status that hindered further treatment, one patient
received only one cycle of treatment and three patients’
FLT-PET scans were not evaluable as their metastases
were too small. Thus, data from the remaining 27
patients were available for further analysis. Patient char-
acteristics are listed in Table 1. All patients received first-
line treatment according to local guidelines. During the
study period, guidelines were slightly altered for patients
without a mutation in the RAS genes (ras-wild-type) from
bevacizumab, capecitabine and oxaliplatin (bev-CAPOX)
to cetuximab, 5-fluorouracil (5-FU; intravenous) and
irinotecan (cet-FOLFIRI), while patients with a RAS muta-
tion continued receiving bev-CAPOX. Capecitabine is an
oral drug given b.i.d. for 2 weeks while 5-FU is given as a
bolus day 1 followed by 46 h on a pump. Bevacizumab,
oxaliplatin and irinotecan is given as a bolus day 1.
The median time interval between the baseline scan
and initiation of treatment was 5 days (range 1–8), and
between initiation of treatment and FLT/PET evaluation
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was 10 days (range 5–15). Images from an FLT-PET/CT
are shown in Fig. 2.
FLT vs. RECIST and survival
Based on RECIST 19 patients (70%) experienced PR,
seven (26%) had SD and one (4%) had PD after three
treatments. The median follow-up time was 27.9 months,
in which 12 patients developed PD and ten died. Seven
patients had a liver resection after three cycles of treat-
ment, and a further nine patients had a liver resection
performed later during their treatment. Follow-up time
was between 24.2 and 43.9 months in patients still alive.
A decrease in FLT uptake measured by SUVmax and
SUVmean was seen in 23 of the 27 patients (85%), with
an equally significant median change of –25% (SUVmax,
p = 0.001; SUVmean, p = 0.005). In the group of non-
responders, no significant change was seen from baseline
to early evaluation (SUVmax, p = 0.12; SUVmean, p = 0.12).
Division of the patients into responders and non-
responders showing their changes in FLT uptake is illus-
trated in Fig. 3.
The patient with PD was the only one without a de-
crease in lesion size. The maximum FLT uptake (SUVmax)
increased in this patient from 5.67 to 6.84 (21%), which
was the highest increase among the patients. Figure 4
illustrates the change in FLT uptake (SUVmax, SUVmean)
compared to the RECIST evaluation for all patients. There
was no statistically significant correlation between the
change in FLT uptake and RECIST outcome (p = 0.24) or
between the change in FLT uptake in responders versus
non-responders (p = 0.71). In contrast, the change in
carcinoembryonic antigen (CEA) from baseline to evalu-
ation correlated with the percentage change in lesion size
(p = 0.015) and with RECIST outcome (p = 0.047). Analys-
ing all 27 evaluated patients (16 of which had a liver resec-
tion), the change in FLT uptake was not related to survival
(p = 0.79, Wald test, Cox regression analysis). An early
increase in FLT uptake (>2%) was a poor predictor of
tumour growth (RECIST) after three cycles of treatment
as the positive predictive value (PPV) was only 0.25. The
negative predictive value (NPV) was 1.
FLT vs. morphology criteria (Chun)
Application of the criteria of Chun et al. [20] to CT
scans distributed the patients into three categories ac-
cording to observed morphologic changes. Nine patients
(33%) had an optimal response, 13 (48%) had an incom-
plete response and three (11%) had no response. Two
patients could not be categorised on the basis of
morphological changes. One patient experienced a near-
complete response, making an estimation of attenuation
difficult, while the other patient was evaluated by MR in-
stead of CT to help the surgical team plan a liver resection.
There was no correlation between the morphological
changes after three cycles of treatment [20], and the
early changes in FLT uptake, neither measured as
SUVmax or SUVmean (p = 0.62; p = 0.94). Likewise, no
correlation found between the morphological changes and
(i) the RECIST characterisation or (ii) the percent change
in tumour size (p = 0.79; p = 0.92). Four patients were
Fig. 1 CONSORT flow diagram
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characterised as having an optimal morphological re-
sponse and yet were classified by RECIST as having SD.
Three patients were categorised to have no morphologic
response. At CT scan, they had either an increase in
tumour size or very modest tumour shrinkage.
Discussion
Imaging reflecting early cellular changes predicting
the response to a given treatment is a non-invasive
approach to personalised medicine. The current clin-
ical means of measuring the clinical response by im-
aging is performed by evaluation using RECIST
which is strictly based on changes in tumour size [1].
Since cellular and molecular changes may precede
changes in tumour volume, new methods are under
investigation [24]. As [18 F]-fluoro-deoxy-glucose (FDG)
not only accumulates in tumour tissue but is also seen in
inflammatory tissue, new tracers more specific for
malignancy are therefore warranted. FLT has been
assessed for use in early response evaluation in a few small
studies and has been found to be superior to FDG in dif-
ferentiating tumour from inflammation [25, 26].
To the best of our knowledge, this study is the largest
study evaluating FLT-PET/CT for early response assess-
ment of chemotherapy-treated CRC patients with liver
metastases. Only one other study has previously evalu-
ated liver metastases as measurable lesions. The study
included a mixture of patients with colorectal and breast
cancer, and a change in FLT could separate responders
from non-responders with a sensitivity of 83% and a spe-
cificity of 78% [17]. Other studies have only evaluated
extrahepatic lesions. A reason may be that 18-F accumu-
lation is high in normal liver tissue because of FLT glu-
curonidation in the hepatocytes [18, 19]. In spite of this
obstacle, we found it important to investigate the FLT
methodology in liver metastases because they very often
are the main target in treatment of CRC. Furthermore,
liver metastases are more suitable for accurate repeated
measurements in contrast to the primary tumour which
may be mobile and therefore difficult to capture in the
same position from scan to scan. A significant decrease
in FLT uptake was seen in the group of responders com-
pared to non-responders; however, this must be inter-
preted cautiously due to the small sample size in the
non-responders’ group. In this patient cohort, looking at
the patients individually, we could not separate re-
sponders from non-responders based on the changes in
FLT uptake.
It can be argued that it is always meaningful to charac-
terise SD according to RECIST as non-responders be-
cause SD may represent lesions decreasing up to 30%
[1]. For the same reason, instead of forcing data to fit
four bins, it has become more and more common to
study treatment outcome in waterfall plots since changes
in tumour size occur as a continuum [27]. In common
clinical practice, SD suggests that the current treatment
regimen is continued since this policy has shown super-
ior survival data in metastatic CRC [28, 29]. In this
study, all patients with SD had a decrease in lesion size,
meaning that the treatment had a beneficial effect. The
key point of early response evaluation is to characterise
true non-responders so that the current treatment can
be discontinued. This is especially important for those
patients with potentially resectable disease where an ag-
gressive approach is necessary to achieve resectability.
Hence, those patients with “true” PD need to be identi-
fied. In this study, the one patient with PD stood out as
having the highest increase in FLT uptake; however, no
conclusion can be drawn from a single patient with PD.
The majority of the patients in this study received a
molecular targeted treatment (70%), in most cases beva-
cizumab. Bevacizumab is an anti-angiogenic drug that
Table 1 Patient characteristics
Characteristics n = 27 Percentage
Gender
Male 15 56%
Female 12 44%
Primary tumour
Right 7 26%
Left 12 44%
Rectum 8 30%
Primary tumour
Resected 11 41%
In situ 16 59%
Metastases
Only liver 13 48%
Lymph nodes 12 44%
Lung 5 19%
Peritoneal carcinosis 2 7%
Chemonaive 27 100%
RAS status
Wild-type 13 48%
Mutated 14 52%
Pre-treatment CEA Mean 279 Range 2–2650 ng/ml
Evaluation CEA Mean 77 Range 2–899 ng/ml
Median age 64 Range 45–84 years
Treatment
CAPOX 4 15%
Bev-CAPOX 16 59%
FOLFIRI 1 4%
Cet-FOLFIRI 3 11%
Pan-FOLPOX 3 11%
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causes morphological changes with a decrease in vascu-
larity followed by a decrease in attenuation and enhance-
ment at imaging even though no changes in tumour size
are necessarily seen. It can therefore be debated whether
it is reasonable to compare FLT/PET to CT using
RECIST because these criteria are often found to be
inadequate when bevacizumab is part of the treatment
[20, 21]. The fact that many liver metastases resected
after neoadjuvant chemotherapy may exhibit a consider-
able degree of necrosis even though no shrinkage has
been proven prior to resection indicates that changes in
tumour size do not always reflect the pathologic re-
sponse [30]. A study by Chun et al. [20] evaluated the
treatment response in CRC liver metastases treated with
chemotherapy, including bevacizumab. They found that
both the morphological changes and RECIST outcome
correlated with the histological evaluation of resected
metastases, focusing on vital tumour cells, but predic-
tion of minor pathological response was significantly
better by morphological changes compared to RECIST.
They also demonstrated a correlation between the mor-
phological changes after three cycles of treatment and
survival; in contrast, no correlation was seen with
RECIST. There are no previous studies on FLT-PET for
response assessment during treatment with bevacizumab
in CRC. However, a preclinical study investigated the
Fig. 2 Left column images show baseline scanning, and right column shows images from the evaluation. a A metastasis is seen on the CT as a
hypodense focus in the right liver lobe. c The corresponding PET/CT reveals slight pathological FLT uptake in the liver metastasis and relatively
high physiological FLT uptake in the normal liver parenchyma. b The metastasis is more hypodense at the time of evaluation and the corresponding
PET/CT. d Decreased FLT uptake as a non-active focus in the right liver lobe. e The primary tumour in rectum (baseline) is visualised on CT with the
corresponding PET/CT. g High FLT uptake in the tumour. Physiological high FLT uptake is seen in the bone marrow and in the normal intestine.
There is no uptake in the uterus in the left side of the pelvis. f At the evaluation, structural shrinkage of the primary tumour on CT is shown and the
corresponding PET/CT. h Normalised FLT uptake in the residual tumour. There is physiological FLT uptake in the bone marrow and in the small
intestine in the left side of the pelvis
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effect of bevacizumab on orthotopic glioblastoma xeno-
grafts and found no changes in FLT when bevacizumab
was administered as monotherapy [31]. Four of the pa-
tients included in the present study were characterised
as having SD but showed a good morphologic response,
reflecting the inadequacy of RECIST for response evalu-
ation of targeted treatments.
Even though this is the largest FLT/PET study per-
formed on humans with CRC liver metastases, the sam-
ple size is still relatively small with too few patients with
PD. Another limitation is the variation of treatment regi-
mens even though this reflects the everyday clinical situ-
ation. It can be debated whether correlation of the early
changes in proliferation measured by changes in FLT
Fig. 3 Changes in FLT uptake from baseline to the day of early evaluation. SUVmax decreased significantly in the group of responders, whereas
the group of non-responders did not show a significant decrease in FLT uptake. The patient with progressive disease is illustrated with a black line
in the group of non-responders
Fig. 4 A waterfall plot of FLT-PET response measured as SUVmax and SUVmean. The percentage change in FLT uptake from baseline to the early
response assessment is plotted on the y-axis and the patients are listed in order of the amount of change on the x-axis. The RECIST characterisations
are colour-coded within the bar graph, showing that the patient with progressive disease has the highest increase in FLT uptake, while the patients
with stable disease and a partial response are intermingled. Left panel: ΔSUVmax. Right panel: ΔSUVmean
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uptake with a RECIST assessment of tumour shrinkage
or a CT morphologic response is best. Our analysis of
changes in FLT uptake and survival was hampered by
the fact that a majority of the patients subsequently had
a liver resection and thereby were potentially cured. In
the ideal setting, all patients should have a liver resection
after three cycles of treatment, thus making it possible
to correlate changes in FLT uptake to the histological
tumour regression, or if no patients were liver resected,
it would be possible to correlate FLT uptake changes to
the entire cohort’s progression-free survival or OS. In
our study, a rather large fraction of the patients (16 out
of 27) did undergo a liver resection, thereby making it
impossible to correlate early changes in FLT uptake to
progression-free survival. It is difficult to predict who
will become resectable for their liver metastases follow-
ing neoadjuvant treatment.
Earlier studies have raised concern about the use of
FLT for early response assessment due to the impact of
the drugs given on the de novo and salvage pathway of
thymidine synthesis. 5-FU inhibits thymidylate synthase
and consequently inhibits the de novo pathway following
a depletion of the thymidine pool necessary for DNA
synthesis. It is known that 5-FU gives rise to an increase
in FLT uptake shortly after the drug is given, termed the
FLT flare. This flare has been explained by a redistribu-
tion of the transporter from the intracellular compart-
ments to the cell surface with no changes in the level of
ATP and TK-1 [32], meaning that FLT reaches the cell
but is not phosphorylated and therefore not trapped in-
side the cell. Previous studies have shown that changes
in FLT uptake seen after this flare reflect the changes in
tumour shrinkage when treated with 5-FU. In our study,
all patients were treated with 5-FU either as an infusion
or as the prodrug capecitabine. The evaluation FLT-PET
scans in this study were performed considerably later
than when the flare is reported to occur [6, 18, 32, 33];
therefore, we do not have any concerns regarding poten-
tial influence from the flare.
Conclusions
In conclusion, we were not able to demonstrate
correlation between early changes on FLT-PET following
the first cycle of treatment and response on subsequent
CT scan, neither when evaluated according to RECIST
or morphology criteria (Chun). Thus, FLT-PET does
not seem to be an applicable methodology for early
response evaluation of mCRC treated with 5-FU
based chemotherapy.
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